CATB
NASDAQ

Catabasis Pharmaceuticals Inc

Overview
CATB
Symbol
NASDAQ
Exchange
About stock

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

Address: 100 High Street, Boston, MA, United States, 02110

Catabasis Pharmaceuticals Inc dividend calculator
Report issue